LambdaVision CEO, Nicole Wagner, sits down with Balerion Advisor, Doug McAdams, to discuss the rise of an innovative artificial retina manufactured in microgravity.
00:00 Welcome & IntroductionsDoug introduces Nicole Wagner and LambdaVision; overview of the webinar’s focus on biotech as an emerging space-economy application.
01:00 Nicole Wagner’s Background & Origins of LambdaVisionPhD in molecular biology; work on light-activated proteins and the founding of LambdaVision out of UConn research.
02:30 What LambdaVision DoesProtein-based artificial retina designed to restore vision in patients with end-stage retinal degeneration.
04:00 From Academic Research to CommercializationChallenges of translating lab science into a company; MassChallenge and early entrepreneurial support.
05:30 Discovery of Space as a Manufacturing AdvantageIntroduction to ISS National Lab and the CASIS Tech in Space Prize; why microgravity matters.
07:00 Layer-by-Layer Manufacturing ExplainedElectrostatic deposition, 200-layer thin films, and why gravity introduces defects on Earth.
09:00 How the Artificial Retina Works BiologicallyReplacing damaged rods and cones; converting light directly into neural signals without external hardware.
11:00 Comparison to Other Retinal TechnologiesAdvantages over bulky hardware solutions and purely therapeutic approaches.
12:30 First ISS Missions & Early ResultsMiniaturizing lab hardware into autonomous “shoebox-scale” payloads; Space Tango partnership.
15:00 SpaceX Launch Experience & Initial Proof of Concept2018 SpaceX CRS-16 flight; demonstrating viable protein layering in microgravity.
16:30 Autonomous Payload DesignMinimal astronaut time, passive payloads, resilience to launch delays.
18:30 Scaling ISS OperationsNine ISS missions to date; improved reproducibility, analytics, and redundancy.
20:00 Looking Beyond the ISSTransition planning as ISS retires; autonomous capsules, CLDs, and platform flexibility.
22:00 Cadence, Cost, and Commercial ViabilityWhy launch frequency and turnaround time matter more than single-mission optimization.
23:30 Manufacturing Constraints for Biotech in SpaceGMP requirements, launch-site proximity, chain of custody, and regulatory compliance.
26:00 Fundraising & Capital Strategy$15–16M in non-dilutive funding; rationale for raising a $7M seed round.
27:30 Investors & Strategic Backers776 Ventures, Aurelia Foundry Fund, Earth to Mars Capital, Seraphim Space.
29:00 FDA Pathway & Regulatory StrategyPre-IND meetings, animal models, manufacturing validation, and IND filing.
32:00 Framing Space Manufacturing for RegulatorsISS as “another manufacturing site” rather than a regulatory anomaly.
34:30 Economics of Space-Manufactured TherapiesWhy high-value implants justify space manufacturing; reimbursement benchmarks.
36:00 Market Size & Disease StrategyRetinitis pigmentosa vs. macular degeneration; orphan disease entry strategy.
38:00 Scaling Production in OrbitMultiple shoebox payloads vs. larger autonomous platforms.
39:30 Timeline to Clinical Trials & RevenueTargeting clinical trials around 2028; potential revenues or acquisition ~2030.
41:00 Role of CLDs and Autonomous Capsules (e.g., Varda)Need for redundancy, multi-platform resilience, and higher flight cadence.
43:00 Building a Space Biomanufacturing EcosystemImportance of multiple “shots on goal” and learning through iteration.
45:00 Community & Knowledge SharingConsortiums, unpublished data, and collaborative learning across space biotech.
47:00 Future Outlook for LambdaVisionLeveraging ISS while preparing for next-generation platforms.
49:00 Closing Thoughts on Space BiomanufacturingWhy this is a pivotal moment for biotech in space; final reflections.
